NEW YORK, NY (December 3, 2007) – Autism Speaks, the largest non-profit organization dedicated to increasing awareness of autism and raising money to fund autism research, today announced that it will host a research symposium on the Development of Novel Neuropharmacological Therapeutics for Autism on December 14, 2007, as a satellite symposium of the 46th annual meeting of the American College of Neuropsychopharmacology (ACNP) in Boca Raton, Fla. The symposium is associated with the main ACNP annual meeting (December 9-13).
The symposium will convene about 100 world-renowned scientists, clinicians and practitioners. It, will focus on advances in basic, clinical and industry-based research and will present an integrated view of the approaches in use to discover and develop novel medications for autism treatment. The program will illustrate recent advances in the field, examine the broad scope of current, exploitable opportunities for drug development, and provide an open forum for discussing barriers to further progress in defining this condition and identifying new therapeutics.
Notable presenters include Mark Bear, Ph.D. of Massachusetts Institute of Technology, Jacqueline Crawley, Ph.D. of the National Institute of Mental Health, Eric Hollander, M.D. of Mount Sinai School of Medicine, Lawrence Scahill, Ph.D. of Yale University, Gwen Zornberg, M.D., Sc.D. of the Food and Drug Administration and other researchers from academia, clinical practice and the pharmaceutical industry. Presentation topics will include clinical trial design and the best ways to test new drug candidates; the complexity of the disorder and the challenges in selecting study participants as well as new technologies that may facilitate this process; novel drug targets; and the role of industry in developing new medicines for these targets.
About Autism Speaks
Autism Speaks is dedicated to increasing awareness of autism spectrum disorders, to funding research into the causes, prevention, treatments and cure for autism, and to advocating for the needs of affected families. It was founded in February 2005 by Suzanne and Bob Wright, the grandparents of a child with autism. Bob Wright is Vice Chairman, General Electric, and served as chief executive officer of NBC for more than twenty years. Autism Speaks has merged with both the National Alliance for Autism Research (NAAR) and Cure Autism Now (CAN), bringing together the nation's three leading autism advocacy organizations. To learn more about Autism Speaks, please visit www.autismspeaks.org.
About the ACNP
The principal function of the American College of Neuropsychopharmacology (ACNP) is to further research and education in neuropsychopharmacology and related fields by specifically: Promoting the interaction of a broad range of scientific disciplines of brain and behavior in order to advance the understanding of prevention and treatment of diseases of the nervous system including psychiatric, neurological, behavioral and addictive disorders; Encouraging scientists to enter research careers in fields related to these disorders and their treatment; and ensuring the dissemination of relevant scientific advances in these disorders.